Biopharmaceutical company Scholar Rock Holding Corp (SRRK) recently announced that regarding the resubmission of its Biologics License Application (BLA), the company expects the U.S. Food and Drug Administration (FDA) to accept the filing within 30 days and initiate the formal review process.

Biopharmaceutical company Scholar Rock Holding Corp (SRRK) recently announced that regarding the resubmission of its Biologics License Application (BLA), the company expects the U.S. Food and Drug Administration (FDA) to accept the filing within 30 days and initiate the formal review process.

老虎证券2026/03/31 11:16

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

The maximum review period is expected to last up to six months, starting from the date of resubmission. The company emphasized that this timeline is consistent with the FDA's standard procedures for handling BLA applications. If the review progresses smoothly, it will pave the way for the subsequent commercialization of related innovative therapies.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Biopharmaceutical company Scholar Rock Holding Corp (SRRK) recently announced that regarding the resubmission of its Biologics License Application (BLA), the company expects the U.S. Food and Drug Administration (FDA) to accept the filing within 30 days and initiate the formal review process.

You may also like

Crypto prices